Sixty subjects ( New York Heart Association -LSB- NYHA -RSB- functional class II-III , left ventricular ejection fraction ( LVEF ) @ % , left ventricular end-diastolic diameter @ mm to < @ mm ) receiving optimal pharmacologic therapy were randomized at @ sites .